APA

Grunenberg A., Kaiser L. M., Woelfle S., Schmelzle B., Viardot A., Möller P., Barth T. F., Muche R., Dreyhaupt J. & Buske C. (20210127). Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. : Future oncology (London, England).

Chicago

Grunenberg Alexander, Kaiser Lisa M, Woelfle Stephanie, Schmelzle Birgit, Viardot Andreas, Möller Peter, Barth Thomas Fe, Muche Rainer, Dreyhaupt Jens and Buske Christian. 20210127. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. : Future oncology (London, England).

Harvard

Grunenberg A., Kaiser L. M., Woelfle S., Schmelzle B., Viardot A., Möller P., Barth T. F., Muche R., Dreyhaupt J. and Buske C. (20210127). Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. : Future oncology (London, England).

MLA

Grunenberg Alexander, Kaiser Lisa M, Woelfle Stephanie, Schmelzle Birgit, Viardot Andreas, Möller Peter, Barth Thomas Fe, Muche Rainer, Dreyhaupt Jens and Buske Christian. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. : Future oncology (London, England). 20210127.